Literature DB >> 25610736

Two in one: improving synthetic long peptide vaccines by combining antigen and adjuvant in one molecule.

Gijs G Zom1, Dmitri V Filippov2, Gijsbert A van der Marel2, Hermen S Overkleeft2, Cornelis J Melief3, Ferry Ossendorp1.   

Abstract

Aiming to increase the potency of synthetic long peptide (SLP)-based cancer vaccines, the Toll-like receptor 2 (TLR2) ligand Pam3CSK4 was conjugated in a chemically defined fashion to SLPs harbouring both cytotoxic T lymphocyte (CTL) and T helper epitopes. We recently showed that these SLP-conjugates induce strong antitumor immunity in murine cancer models.

Entities:  

Keywords:  SLP; TLR2; Toll-like receptor; Tumor; conjugate; immunotherapy; lymphoma; melanoma; synthetic long peptides; vaccination

Year:  2014        PMID： 25610736      PMCID： PMC4292239          DOI： 10.4161/21624011.2014.947892

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  11 in total

1.  Efficient induction of antitumor immunity by synthetic toll-like receptor ligand-peptide conjugates.

Authors:  Gijs G Zom; Selina Khan; Cedrik M Britten; Vinod Sommandas; Marcel G M Camps; Nikki M Loof; Christina F Budden; Nico J Meeuwenoord; Dmitri V Filippov; Gijsbert A van der Marel; Hermen S Overkleeft; Cornelis J M Melief; Ferry Ossendorp
Journal:  Cancer Immunol Res       Date:  2014-04-21       Impact factor: 11.151

Review 2.  TLR ligand-peptide conjugate vaccines: toward clinical application.

Authors:  Gijs G P Zom; Selina Khan; Dmitri V Filippov; Ferry Ossendorp
Journal:  Adv Immunol       Date:  2012       Impact factor: 3.543

3.  Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909.

Authors:  Daniel E Speiser; Danielle Liénard; Nathalie Rufer; Verena Rubio-Godoy; Donata Rimoldi; Ferdy Lejeune; Arthur M Krieg; Jean-Charles Cerottini; Pedro Romero
Journal:  J Clin Invest       Date:  2005-03       Impact factor: 14.808

4.  The long-term immune response after HPV16 peptide vaccination in women with low-grade pre-malignant disorders of the uterine cervix: a placebo-controlled phase II study.

Authors:  Peggy J de Vos van Steenwijk; Mariette I E van Poelgeest; Tamara H Ramwadhdoebe; Margriet J G Löwik; Dorien M A Berends-van der Meer; Caroline E van der Minne; Nikki M Loof; Linda F M Stynenbosch; Lorraine M Fathers; A Rob P M Valentijn; Jaap Oostendorp; Elisabeth M Osse; Gert Jan Fleuren; Linda Nooij; Marjolein J Kagie; Bart W J Hellebrekers; Cornelis J M Melief; Marij J P Welters; Sjoerd H van der Burg; Gemma G Kenter
Journal:  Cancer Immunol Immunother       Date:  2013-11-15       Impact factor: 6.968

5.  Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia.

Authors:  Gemma G Kenter; Marij J P Welters; A Rob P M Valentijn; Margriet J G Lowik; Dorien M A Berends-van der Meer; Annelies P G Vloon; Farah Essahsah; Lorraine M Fathers; Rienk Offringa; Jan Wouter Drijfhout; Amon R Wafelman; Jaap Oostendorp; Gert Jan Fleuren; Sjoerd H van der Burg; Cornelis J M Melief
Journal:  N Engl J Med       Date:  2009-11-05       Impact factor: 91.245

6.  Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.

Authors:  Marij J P Welters; Gemma G Kenter; Sytse J Piersma; Annelies P G Vloon; Margriet J G Löwik; Dorien M A Berends-van der Meer; Jan W Drijfhout; A Rob P M Valentijn; Amon R Wafelman; Jaap Oostendorp; Gert Jan Fleuren; Rienk Offringa; Cornelis J M Melief; Sjoerd H van der Burg
Journal:  Clin Cancer Res       Date:  2008-01-01       Impact factor: 12.531

7.  Distinct uptake mechanisms but similar intracellular processing of two different toll-like receptor ligand-peptide conjugates in dendritic cells.

Authors:  Selina Khan; Martijn S Bijker; Jimmy J Weterings; Hans J Tanke; Gosse J Adema; Thorbald van Hall; Jan W Drijfhout; Cornelis J M Melief; Hermen S Overkleeft; Gijsbert A van der Marel; Dmitri V Filippov; Sjoerd H van der Burg; Ferry Ossendorp
Journal:  J Biol Chem       Date:  2007-04-26       Impact factor: 5.157

8.  N-tetradecylcarbamyl lipopeptides as novel agonists for Toll-like receptor 2.

Authors:  Marian M J H P Willems; Gijs G Zom; Selina Khan; Nico Meeuwenoord; Cornelis J M Melief; Mario van der Stelt; Herman S Overkleeft; Jeroen D C Codée; Gijsbert A van der Marel; Ferry Ossendorp; Dmitri V Filippov
Journal:  J Med Chem       Date:  2014-07-23       Impact factor: 7.446

9.  Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors.

Authors:  F Ossendorp; E Mengedé; M Camps; R Filius; C J Melief
Journal:  J Exp Med       Date:  1998-03-02       Impact factor: 14.307

Review 10.  TLR Agonists for Cancer Immunotherapy: Tipping the Balance between the Immune Stimulatory and Inhibitory Effects.

Authors:  Hailing Lu
Journal:  Front Immunol       Date:  2014-03-03       Impact factor: 7.561
View more
  8 in total

1.  Intracellular Cleavable CpG Oligodeoxynucleotide-Antigen Conjugate Enhances Anti-tumor Immunity.

Authors:  Katrin Kramer; Nicholas J Shields; Viola Poppe; Sarah L Young; Greg F Walker
Journal:  Mol Ther       Date:  2017-01-04       Impact factor: 11.454

2.  Targeting self and neo-epitopes with a modular self-adjuvanting cancer vaccine.

Authors:  Elodie Belnoue; Jean-François Mayol; Susanna Carboni; Wilma Di Berardino Besson; Eloise Dupuychaffray; Annika Nelde; Stefan Stevanovic; Marie-Laure Santiago-Raber; Paul R Walker; Madiha Derouazi
Journal:  JCI Insight       Date:  2019-04-23

3.  Lipid A analog CRX-527 conjugated to synthetic peptides enhances vaccination efficacy and tumor control.

Authors:  Elena Tondini; Niels R M Reintjens; Giulia Castello; Tsolere Arakelian; Marjolein Isendoorn; Marcel Camps; Jana Vree; Gijs A van der Marel; Dmitri V Filippov; Jeroen D C Codee; Ferry Ossendorp
Journal:  NPJ Vaccines       Date:  2022-06-23       Impact factor: 9.399

Review 4.  Novel tumour antigens and the development of optimal vaccine design.

Authors:  Victoria A Brentville; Suha Atabani; Katherine Cook; Lindy G Durrant
Journal:  Ther Adv Vaccines Immunother       Date:  2018-04-10

5.  Combination vaccine based on citrullinated vimentin and enolase peptides induces potent CD4-mediated anti-tumor responses.

Authors:  Victoria A Brentville; Rachael L Metheringham; Ian Daniels; Suha Atabani; Peter Symonds; Katherine W Cook; Mireille Vankemmelbeke; Ruhul Choudhury; Poonam Vaghela; Mohamed Gijon; Ghislaine Meiners; Willem-Jan Krebber; Cornelis J M Melief; Lindy G Durrant
Journal:  J Immunother Cancer       Date:  2020-06       Impact factor: 13.751

Review 6.  Current Strategies to Enhance Anti-Tumour Immunity.

Authors:  Katherine W Cook; Lindy G Durrant; Victoria A Brentville
Journal:  Biomedicines       Date:  2018-03-23

Review 7.  Opportunities for Conventional and in Situ Cancer Vaccine Strategies and Combination with Immunotherapy for Gastrointestinal Cancers, A Review.

Authors:  Rachid Bouzid; Maikel Peppelenbosch; Sonja I Buschow
Journal:  Cancers (Basel)       Date:  2020-04-30       Impact factor: 6.639

8.  TLR2 ligand-synthetic long peptide conjugates effectively stimulate tumor-draining lymph node T cells of cervical cancer patients.

Authors:  Gijs G Zom; Marij J P Welters; Nikki M Loof; Renske Goedemans; Sinéad Lougheed; Rob R P M Valentijn; Maarten L Zandvliet; Nico J Meeuwenoord; Cornelis J M Melief; Tanja D de Gruijl; Gijsbert A Van der Marel; Dmitri V Filippov; Ferry Ossendorp; Sjoerd H Van der Burg
Journal:  Oncotarget       Date:  2016-10-11
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.